While the AstraZeneca at ASCO 2020 presentation was virtual this year, the phase III results from AstraZeneca’s drug Tagrisso, in lung cancer patients, were as real as they could get. 89% of patients treated with Tagrisso were alive and cancer-free after two years, compared to 53% of patients treated with the placebo. Oncology Dominance AstraZeneca